VYGR Executive Compensation
* In USD (Original Currency)|
Filing Date (SEC Report) |
Year | Reporting Name | Salary | Bonus | Stock Award | Incentive Plan Compensation | Other Compensation | Total |
|---|---|---|---|---|---|---|---|---|
| 2024-04-25 | 2022 | Alfred Sandrock, M.D., Ph.D. Chief Executive Officer, President, and Director | 525,414 | 50,000 | 855,000 | 250,000 | 10,385 | 7,406,449 |
| 2024-04-25 | 2023 | Alfred Sandrock, M.D., Ph.D. Chief Executive Officer, President, and Director | 624,000 | 0 | 891,600 | 377,520 | 13,050 | 3,172,433 |
| 2024-04-25 | 2023 | Robin Swartz | 449,400 | 0 | 297,200 | 199,534 | 13,050 | 1,381,272 |
| 2024-04-25 | 2023 | Jacquelyn Fahey Sandell | 207,692 | 0 | 472,750 | 93,960 | 7,010 | 1,677,297 |
| 2023-04-27 | 2021 | Michael Higgins Former Interim President and Chief Executive Officer | 379,181 | 0 | 0 | 0 | 0 | 696,063 |
| 2023-04-27 | 2022 | Michael Higgins Former Interim President and Chief Executive Officer | 235,727 | 0 | 128,834 | 0 | 0 | 757,533 |
| 2023-04-27 | 2021 | Peter P. Pfreundschuh Chief Financial Officer | 0 | 0 | 0 | 0 | 0 | 0 |
| 2023-04-27 | 2022 | Peter P. Pfreundschuh Chief Financial Officer | 122,500 | 0 | 740,000 | 50,229 | 0 | 1,791,949 |
| 2023-04-27 | 2021 | Alfred Sandrock, M.D., Ph.D. Chief Executive Officer, President, and Director | 0 | 0 | 0 | 0 | 0 | 0 |
| 2023-04-27 | 2022 | Alfred Sandrock, M.D., Ph.D. Chief Executive Officer, President, and Director | 525,414 | 50,000 | 855,000 | 250,000 | 0 | 7,396,064 |
| 2023-04-27 | 2021 | Robert W. Hesslein Senior Vice President and General Counsel | 430,000 | 0 | 415,420 | 141,106 | 0 | 1,309,444 |
| 2023-04-27 | 2022 | Robert W. Hesslein Senior Vice President and General Counsel | 450,754 | 0 | 57,000 | 175,433 | 0 | 914,571 |
| 2022-04-21 | 2021 | G. Andre Turenne Former President and Chief Executive Officer | 600,300 | 0 | 1,132,220 | 0 | 0 | 2,630,096 |
| 2022-04-21 | 2020 | G. Andre Turenne Former President and Chief Executive Officer | 580,000 | 0 | 1,053,000 | 293,480 | 0 | 3,274,275 |
| 2022-04-21 | 2021 | Michael Higgins | 379,181 | 0 | 0 | 0 | 0 | 696,063 |
| 2022-04-21 | 2021 | Robert W. Hesslein Senior Vice President and General Counsel | 435,511 | 0 | 415,420 | 141,106 | 0 | 1,314,955 |
| 2022-04-21 | 2020 | Robert W. Hesslein Senior Vice President and General Counsel | 420,784 | 0 | 356,400 | 157,037 | 2,829 | 1,393,160 |
| 2022-04-21 | 2021 | Allison Dorval Former Chief Financial Officer | 393,185 | 0 | 415,420 | 0 | 0 | 1,131,523 |
| 2022-04-21 | 2020 | Allison Dorval Former Chief Financial Officer | 403,104 | 0 | 356,400 | 150,438 | 550 | 1,366,602 |
| 2022-04-21 | 2021 | Omar Khwaja, M.D., Ph.D. Former Chief Medical Officer and Head of Research and Development | 196,835 | 0 | 457,780 | 0 | 0 | 996,529 |
| 2022-04-21 | 2020 | Omar Khwaja, M.D., Ph.D. Former Chief Medical Officer and Head of Research and Development | 449,514 | 0 | 388,800 | 165,421 | 144,077 | 1,645,386 |
| 2022-04-21 | 2021 | Glenn Pierce, M.D., Ph.D. | 293,272 | 0 | 0 | 0 | 0 | 552,679 |
| 2021-04-22 | 2019 | Omar Khwaja, M.D., Ph.D. Chief Medical Officer and Head of Research and Development | 271,206 | 100,000 | 0 | 167,200 | 160,184 | 3,815,769 |
| 2021-04-22 | 2020 | Robert W. Hesslein Senior Vice President and General Counsel | 420,784 | 0 | 0 | 157,037 | 2,829 | 1,393,160 |
| 2021-04-22 | 2019 | Robert W. Hesslein Senior Vice President and General Counsel | 307,500 | 0 | 0 | 134,500 | 0 | 3,240,961 |
| 2021-04-22 | 2020 | G. Andre Turenne President and Chief Executive Officer | 580,000 | 0 | 0 | 293,480 | 0 | 3,274,076 |
| 2021-04-22 | 2019 | G. Andre Turenne President and Chief Executive Officer | 540,800 | 0 | 0 | 256,880 | 0 | 2,844,090 |
| 2021-04-22 | 2020 | Omar Khwaja, M.D., Ph.D. Chief Medical Officer and Head of Research and Development | 449,514 | 0 | 0 | 165,421 | 144,077 | 1,645,386 |
| 2020-04-22 | 2019 | G. Andre Turenne President and Chief Executive Officer | 540,800 | 0 | 0 | 256,880 | 0 | 2,844,090 |
| 2020-04-22 | 2018 | G. Andre Turenne President and Chief Executive Officer | 240,000 | 0 | 0 | 143,325 | 0 | 8,209,845 |
| 2020-04-22 | 2019 | Omar Khwaja, M.D., Ph.D. | 271,206 | 100,000 | 0 | 167,200 | 160,184 | 3,815,769 |
| 2020-04-22 | 2019 | Robert W. Hesslein | 307,500 | 0 | 0 | 134,500 | 0 | 3,240,961 |
| 2019-04-23 | 2018 | G. Andre Turenne | 0 | 0 | 0 | 0 | 0 | 0 |
| 2019-04-23 | 2017 | Dinah Sah, Ph.D. Chief Scientific Officer | 0 | 0 | 0 | 0 | 0 | 0 |
| 2019-04-23 | 2017 | Matthew P. Ottmer Chief Operating Officer | 0 | 0 | 0 | 0 | 0 | 0 |
| 2019-04-23 | 2018 | Matthew P. Ottmer Chief Operating Officer | 0 | 0 | 0 | 0 | 0 | 0 |
| 2019-04-23 | 2018 | Dinah Sah, Ph.D. Chief Scientific Officer | 0 | 0 | 0 | 0 | 0 | 0 |
| 2019-04-23 | 2017 | Steven M. Paul, M.D. Former President and Chief Executive Officer | 0 | 0 | 0 | 0 | 0 | 0 |
| 2019-04-23 | 2018 | Steven M. Paul, M.D. Former President and Chief Executive Officer | 0 | 0 | 0 | 0 | 0 | 0 |
| 2018-04-27 | 2016 | Matthew P. Ottmer Chief Operating Officer | 0 | 0 | 0 | 0 | 0 | 0 |
| 2018-04-27 | 2017 | Jane Pritchett Henderson Chief Financial Officer and Senior Vice President of Corporate Development | 370,000 | 0 | 0 | 119,318 | 80,417 | 2,246,682 |
| 2018-04-27 | 2016 | Steven M. Paul, M.D. President and Chief Executive Officer | 485,100 | 0 | 0 | 242,550 | 18,304 | 3,435,514 |
| 2018-04-27 | 2017 | Steven M. Paul, M.D. President and Chief Executive Officer | 506,900 | 0 | 0 | 239,510 | 48,303 | 2,655,385 |
| 2018-04-27 | 2017 | Matthew P. Ottmer Chief Operating Officer | 124,359 | 0 | 0 | 132,300 | 0 | 2,829,384 |
| 2018-04-27 | 2016 | Jane Pritchett Henderson Chief Financial Officer and Senior Vice President of Corporate Development | 0 | 0 | 0 | 0 | 0 | 0 |
| 2017-04-25 | 2016 | Steven M. Paul, M.D. President and Chief Executive Officer | 485,100 | 0 | 0 | 242,550 | 18,304 | 3,435,514 |
| 2017-04-25 | 2015 | Robert Pietrusko, Pharm.D. Senior Vice President, Regulatory Affairs and Quality Assurance | 336,400 | 0 | 0 | 76,020 | 50,000 | 551,279 |
| 2017-04-25 | 2016 | Robert Pietrusko, Pharm.D. Senior Vice President, Regulatory Affairs and Quality Assurance | 343,100 | 0 | 0 | 102,930 | 50,000 | 924,299 |
| 2017-04-25 | 2015 | Dinah Sah, Ph.D. Chief Scientific Officer | 315,000 | 0 | 0 | 78,750 | 0 | 819,923 |
| 2017-04-25 | 2016 | Dinah Sah, Ph.D. Chief Scientific Officer | 330,800 | 0 | 0 | 99,240 | 0 | 1,142,485 |
| 2017-04-25 | 2015 | Steven M. Paul, M.D. President and Chief Executive Officer | 450,000 | 0 | 0 | 203,400 | 18,558 | 1,072,829 |
| 2016-04-22 | 2014 | Steven M. Paul, M.D. President & Chief | 150,000 | 0 | 0 | 0 | 5,870 | 1,032,820 |
| 2016-04-22 | 2014 | Bernard Ravina, M.D. Vice President, Clinical | 231,731 | 66,060 | 0 | 0 | 0 | 387,791 |
| 2016-04-22 | 2015 | Bernard Ravina, M.D. Vice President, Clinical | 309,000 | 35,000 | 0 | 77,250 | 0 | 474,763 |
| 2016-04-22 | 2014 | Robert Pietrusko, Pharm.D. Senior Vice President, | 174,792 | 1,161 | 0 | 0 | 50,000 | 350,953 |
| 2016-04-22 | 2015 | Robert Pietrusko, Pharm.D. Senior Vice President, | 336,400 | 0 | 0 | 76,020 | 50,000 | 551,279 |
| 2016-04-22 | 2015 | Steven M. Paul, M.D. President & Chief | 450,000 | 0 | 0 | 203,400 | 18,558 | 1,072,829 |
Disclaimer: The data contained in this website is not necessarily real-time nor accurate. All derived (stocks, indexes, futures) and Forex prices are not provided by exchanges but rather by our third party API www.financialmodellingprep.com, and so prices may not be accurate and may differ from the actual market price, meaning prices are indicative and not appropriate for trading purposes. Therefore, Discounting Cash Flows Inc. doesn't bear any responsibility for any trading losses you might incur as a result of using this data. Discounting Cash Flows Inc. or anyone involved with Discounting Cash Flows Inc. will not accept any liability for loss or damage as a result of reliance on the information including data, quotes, charts and buy/sell signals contained within this website. Please be fully informed regarding the risks and costs associated with trading the financial markets, it is one of the riskiest investment forms possible.
